<DOC>
	<DOCNO>NCT01616680</DOCNO>
	<brief_summary>The purpose research test safety efficacy brentuximab vedotin patient acute skin graft-versus-host disease ( GVHD )</brief_summary>
	<brief_title>Brentuximab Vedotin Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether complete partial response rate steroid-resistant skin GVHD exceed 25 % administration brentuximab vedotin . SECONDARY OBJECTIVES : I . Evaluate effect brentuximab vedotin clinical manifestation acute GVHD liver gastrointestinal tract . II . Determine incidence degree brentuximab vedotin-related toxicity administer allogeneic hematopoietic cell transplantation ( HCT ) . III . Evaluate cluster differentiation ( CD ) 30 expression skin biopsy administration brentuximab vedotin . IV . Enumerate CD30 express lymphocyte blood measure concentration soluble CD30 serum administration brentuximab vedotin . V. Determine whether change CD30 expression skin biopsy blood lymphocytes concentration CD30 serum administration brentuximab vedotin correlate change skin GVHD stage . VI . Evaluate pharmacokinetics ( PK ) brentuximab vedotin patient allogeneic HCT . OUTLINE : This dose escalation study . Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 , 8 , 15 . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients steroidresistant stage 2 3 acute GVHD skin without involvement organ ; patient must receive initial therapy prednisone methylprednisolone prednisoneequivalent dose least 1.0 mg/kg/day alone combined agent , include psoralen ultraviolet A ( PUVA ) , : Flare rash involve least 25 % body surface time start prednisone GVHD treatment , OR Rash involve 50 % body surface persist least 1 week initial treatment , OR Rash involve least 25 % body surface persist least 2 week initial treatment Concomitant use steroid permit ; steroid dose increase within week prior enrollment Patient , guardian legally authorize representative able willing provide inform consent Willing use effective contraception ; woman childbearing potential men partner childbearing potential must agree use effective contraceptive method study 30 day last dose study drug Prior secondline systemic treatment GVHD Absolute neutrophil count ( ANC ) &lt; 2000/μL Administration growth factor order maintain ANC &gt; 2000/μL Platelet count &lt; 30,000/μL , ( unsupported ) Serum total bilirubin concentration &gt; upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3X ULN Calculated creatinine clearance &lt; 60 ml/min Peripheral neuropathy : clinical total neuropathy score ( TNS ) score &gt; 2 Any Grade 3 high uncontrolled active infection within 1 week enrollment Bullous formation desquamation relate GVHD ( stage 4 skin GVHD ) Evidence recurrent/persistent malignancy cytogenetics , histology flow cytometry GVHD donor lymphocyte infusion ( DLI ) Clinical manifestation chronic skin GVHD Women pregnant lactating ; woman childbearing potential must negative serum urine betahuman chorionic gonadotropin ( betahCG ) pregnancy test result within 7 day first dose brentuximab vedotin ; woman nonchildbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy Patients know hypersensitivity brentuximab vedotin History Progressive multifocal leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>